CD47 and neoplasm: CPMV VNPs have also been administered in combination with CD47-blocking antibodies (Wang and Steinmetz, 2019) which proved to have synergistic effects in combating tumor growth in murine ovarian tumor models, where it activated phagocytes, leading to stimulation of the adaptive immune response.